EPIPEN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7449012 | MYLAN SPECIALITY LP | Automatic injector |
Sep, 2025
(1 year, 4 months from now) | |
| US8048035 | MYLAN SPECIALITY LP | Automatic injector with needle cover |
Sep, 2025
(1 year, 4 months from now) | |
| US9586010 | MYLAN SPECIALITY LP | Automatic injector with needle cover |
Sep, 2025
(1 year, 4 months from now) | |
| US8870827 | MYLAN SPECIALITY LP | Automatic injector |
Sep, 2025
(1 year, 4 months from now) | |
| US7794432 | MYLAN SPECIALITY LP | Automatic injector with kickback attenuation |
Sep, 2025
(1 year, 4 months from now) | |
Epipen is owned by Mylan Speciality Lp.
Epipen contains Epinephrine.
Epipen has a total of 5 drug patents out of which 0 drug patents have expired.
Epipen was authorised for market use on 03 August, 1995.
Epipen is available in injectable;intramuscular, subcutaneous dosage forms.
The generics of Epipen are possible to be released after 11 September, 2025.
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 03 August, 1995
Treatment: NA
Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
How can I launch a generic of EPIPEN before it's drug patent expiration?
More Information on Dosage
EPIPEN family patents
